31.07.2023  22:00:00 Zm. - Wolumen Bid01:50:09 Ask01:50:09 Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
1,0300USD - 5,93 mln
Obrót: 5,61 mln
1,0200Wolumen Bid: - 1,0400Wolumen Ask: - 211,42 mlnUSD - -

Opis działalności

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets five hematology/oncology drugs, and expects an FDA decision on another hematology drug later this year. Additionally, Spectrum's pipeline includes three drugs targeting blockbuster markets in advanced stages of clinical development. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies.
 

Zarząd & Rada nadzorcza

CEO
Joseph Turgeon
Zarząd
Kurt Gustafson, Francois Lebel, Keith M. McGahan, Thomas J. Riga
Rada nadzorcza
William L. Ashton, Bernice R. Welles, Dolatrai M. Vyas, Jeffrey L. Vacirca, Joseph W. Turgeon, Nora Brennan, Seth H.Z. Fischer
 

Dane firmy

Nazwa: Spectrum Pharmaceuticals Inc.
Adres: 11500 S. Eastern Avenue, Suite 240,Henderson, NV 89052, USA
Telefon: +1-702-935-6300
Fax: +1-702-260-7405
E-mail: -
Internet: https://www.sppirx.com/
Przemysł: Biotechnologia
Sektor: Biotechnologia
Podsektor: Biotechnologia
Koniec roku finansowego: 31.12
Free float: 61,22%
Data IPO: -

Relacje inwestorskie

Nazwa: Shiv Kapoor
Telefon: -
Fax: -
E-mail: IR@sppirx.com

Główni akcjonariusze

Freefloat
 
61,22%
BlackRock, Inc
 
17,95%
The Vanguard Group
 
7,81%
PRIMECAP Management Company
 
6,83%
Armistice Capital, LLC
 
6,19%